Kidney Diseases最新文献

{"title":"Nephropathy Is Aggravated by Fatty Acids in Diabetic Kidney Disease through Tubular Epithelial Cell Necroptosis and Is Alleviated by an RIPK-1 Inhibitor","authors":"Qi Yu, Ying Chen, Youlu Zhao, Shuo Huang, Xiaohong Xin, Lei Jiang, Hui Wang, Wen-yan Wu, L. Qu, Chengang Xiang, Suxia Wang, Gang Liu, Li Yang","doi":"10.1159/000529995","DOIUrl":"https://doi.org/10.1159/000529995","url":null,"abstract":"Introduction: Diabetic kidney disease (DKD), one of the leading causes of end-stage renal disease, has complex pathogenic mechanisms and few effective clinical therapies. DKD progression is accompanied by the loss of renal resident cells, followed by chronic inflammation and extracellular matrix deposition. Necroptosis is a newly discovered form of regulated cell death and is a major form of intrinsic cell loss in certain diabetic complications such as cardiomyopathy, intestinal disease, and retinal neuropathy; however, its significance in DKD is largely unknown. Methods: In this study, the expression of necroptosis marker phosphorylated MLKL (p-MLKL) in renal biopsy tissues of patients with DKD was detected using immunofluorescence and semiquantified using immunohistochemistry. The effects of different disease-causing factors on necroptosis activation in human HK-2 cells were evaluated using immunofluorescence and Western blotting. db/db diabetic mice were fed a high-fat diet to establish an animal model of DKD with significant renal tubule damage. Mice were treated with the RIPK1 inhibitor RIPA-56 to evaluate its renal protective effects. mRNA transcriptome sequencing was used to explore the changes in signaling pathways after RIPA-56 treatment. Oil red O staining and electron macroscopy were used to observe lipid droplet accumulation in renal biopsy tissues and mouse kidney tissues. Results: Immunostaining of phosphorylated RIPK1/RIPK3/MLKL verified the occurrence of necroptosis in renal tubular epithelial cells of patients with DKD. The level of the necroptosis marker p-MLKL correlated positively with the severity of renal functional, pathological damages, and lipid droplet accumulation in patients with DKD. High glucose and fatty acids were the main factors causing necroptosis in human renal tubular HK-2 cells. Renal function deterioration and renal pathological injury were accelerated, and the necroptosis pathway was activated in db/db mice fed a high-fat diet. Application of RIPA-56 effectively reduced the degree of renal injury, inhibited the necroptosis pathway activation, and reduced necroinflammation and lipid droplet accumulation in the renal tissues of db/db mice fed a high-fat diet. Conclusion: The present study revealed the role of necroptosis in the progression of DKD and might provide a new therapeutic target for the treatment of DKD.","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"15 1","pages":"408 - 423"},"PeriodicalIF":3.7,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82471512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes in Patients on Hemodialysis with Congestive Heart Failure.","authors":"Xinju Zhao,&nbsp;Liangying Gan,&nbsp;Qingyu Niu,&nbsp;Fan Fan Hou,&nbsp;Xinling Liang,&nbsp;Xiaonong Chen,&nbsp;Yuqing Chen,&nbsp;Junhui Zhao,&nbsp;Keith McCullough,&nbsp;Zhaohui Ni,&nbsp;Li Zuo","doi":"10.1159/000529802","DOIUrl":"https://doi.org/10.1159/000529802","url":null,"abstract":"<p><strong>Introduction: </strong>Congestive heart failure (CHF) is one of the common complications in patients with end-stage kidney disease. In the general population, CHF increases the risk of the death. However, there is no well-designed relevant study in the Chinese hemodialysis (HD) population addressing the risks associated with CHF. The aim of this study was to explore the impact of CHF on clinical outcomes in HD patients.</p><p><strong>Methods: </strong>Data from a prospective cohort study, the China Dialysis Outcomes and Practice Patterns Study (DOPPS) 5 (2012-2015), were analyzed. Demographic data, comorbidities, lab data, and death records were extracted. CHF was defined by the diagnosis records upon study inclusion. Our primary outcome was all-cause and cardiovascular (CV) mortality; secondary outcomes were all-cause and cause-specific hospitalization risk. Associations between CHF and outcomes were evaluated using Cox regression models. Stepwise multivariate logistic regression was used to identify the related risk factors, and subgroup analyses were carried out.</p><p><strong>Results: </strong>Of 1,411 patients without missing CHF history information, 24.1% (340) had CHF diagnosis at enrollment. The overall mortality rates were 21.8% versus 12.0% (<i>p</i> < 0.001) in patients with and without CHF during follow-up, respectively. CHF was associated with higher all-cause mortality (adjusted HR: 1.72, 95% confidence interval [CI]: 1.17-2.53, <i>p</i> = 0.006), and the association with CV death was of similar magnitude (HR: 1.60, 95% CI: 0.91-2.81, <i>p</i> = 0.105). CHF patients had more episodes of hospitalization due to heart failure (HR: 2.93, 95% CI: 1.49-5.76, <i>p</i> < 0.01). However, compared with patients without CHF, the all-cause hospitalization risk was not much higher in CHF patients (HR: 1.09, 95% CI: 0.90-1.33, <i>p</i> = 0.39). Subgroup analysis found that the effect of CHF on all-cause mortality was stronger for male patients, patients with residual renal function, the elderly (≥60 years of age), patients with arteriovenous fistulae vascular accesses, nondiabetic patients, low-flux dialyzer users, and inadequately dialyzed patients (standardized Kt/V <2).</p><p><strong>Conclusion: </strong>In HD patients, CHF was found to be associated with a higher risk of all-cause mortality and cause-specific hospitalization risk. Further research is needed to identify opportunities to improve care for HD patients combined with CHF.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"9 4","pages":"306-316"},"PeriodicalIF":3.7,"publicationDate":"2023-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining Biventricular Abnormalities by Cardiac Magnetic Resonance in Pre-Dialysis Patients with Chronic Kidney Disease.","authors":"Li Qi,&nbsp;Beibei Zhi,&nbsp;Jun Zhang,&nbsp;Lingyan Zhang,&nbsp;Song Luo,&nbsp;Longjiang Zhang","doi":"10.1159/000529526","DOIUrl":"https://doi.org/10.1159/000529526","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to investigate biventricular structural and functional abnormalities in pre-dialysis patients across stages of chronic kidney disease (CKD) by cardiac magnetic resonance (CMR).</p><p><strong>Methods: </strong>Fifty-one CKD patients with CMR exams were retrospectively analyzed. Patients were divided into three groups according to estimated glomerular filtration rate (eGFR): CKD 1 group (patients with normal eGFR≥90 mL/min/1.73 m², <i>n</i> = 20), CKD 2-3 group (patients with eGFR< 90 to ≥30 mL/min/1.73 m², <i>n</i> = 14), and CKD 4-5 group (patients with eGFR<30 mL/min/1.73 m², <i>n</i> = 17). Twenty-one age- and sex-matched healthy controls (HC) were recruited. CMR-derived left ventricular (LV) and right ventricular (RV) structural and functional measures were compared. Association between CMR parameters and clinical measures was assessed.</p><p><strong>Results: </strong>There was an increasing trend in RV mass index (RVMi) and LV mass index (LVMi) with the occurrence and development of CKD from HC group to CKD 4-5 group although no significant difference was observed between CKD 1 group and HC group. LV global radial strain and LV global circumferential strain dropped and native T1 value elevated significantly in CKD 4-5 group compared with the other three groups (all <i>p</i> < 0.05), while RV strain measures, RV ejection fraction, and LV ejection fraction showed no significant difference among 4 groups (all <i>p</i> > 0.05). Elevated LV end-diastolic volume index (<i>β</i> = 0.356, <i>p</i> = 0.016) and RV end-systolic volume index (<i>β</i> = 0.488, <i>p</i> = 0.001) were independently associated with RVMi. Increased systolic blood pressure (<i>β</i> = 0.309, <i>p</i> = 0.004), LV end-systolic volume index (<i>β</i> = 0.633, <i>p</i> < 0.001), and uric acid (<i>β</i> = 0.261, <i>p</i> = 0.013) were independently associated with LVMi. Meanwhile, serum phosphorus (<i>β</i> = 0.519, <i>p</i> = 0.001) was independently associated with native T1 value.</p><p><strong>Conclusion: </strong>In pre-dialysis CKD patients, left and right ventricular remolding has occurred. RVMi and LVMi were the first changed CMR indexes in the development of CKD when eGFR began to drop. Because fluid volume overload was the independent risk factor for RVMi and LVMi increase, reasonable controlling fluid volume overload may slow down the progression of biventricular remolding and may reduce related cardiovascular disease risk.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"9 4","pages":"277-284"},"PeriodicalIF":3.7,"publicationDate":"2023-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71412814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgement to Reviewers","authors":"","doi":"10.1159/000534880","DOIUrl":"https://doi.org/10.1159/000534880","url":null,"abstract":"","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"141 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135759228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Front & Back Matter","authors":"","doi":"10.1159/000531309","DOIUrl":"https://doi.org/10.1159/000531309","url":null,"abstract":"","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"46 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80486629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Vol. 8, 2022","authors":"Zhi-Hong Liu, Jeffrey B. Kopp","doi":"10.1159/000528127","DOIUrl":"https://doi.org/10.1159/000528127","url":null,"abstract":"Chunsun Dai – Nanjing Medical University, Nanjing, China Zheng Dong – Augusta University, Augusta, GA, USA Chuan-Ming Hao – Fudan University, Shanghai, China John Cijiang He – Icahn School of Medicine at Mount Sinai, New York, NY, USA Gui-Sen Li – Sichuan Provincial People’s Hospital, Sichuan, China Jing Nie – Southern Medical University, Guangzhou, China Jan Novak – University of Alabama at Birmingham, Birmingham, AL, USA Fan Yi – Shandong University, Jinan, China Shengqiang Yu – Second Military Medical University, Shanghai, China Aihua Zhang – Nanjing Medical University, Nanjing, China Hong Zhang – Peking University, Beijing, China Jinghong Zhao – Third Military Medical University, Chongqing, China","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"1 1","pages":"I - VI"},"PeriodicalIF":3.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88784659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KYA1797K, a Novel Small Molecule Destabilizing β-Catenin, Is Superior to ICG-001 in Protecting against Kidney Aging.","authors":"Mingsheng Zhu,&nbsp;Xian Ling,&nbsp;Shan Zhou,&nbsp;Ping Meng,&nbsp;Qiyan Chen,&nbsp;Shuangqin Chen,&nbsp;Kunyu Shen,&nbsp;Chao Xie,&nbsp;Yaozhong Kong,&nbsp;Maosheng Wang,&nbsp;Lili Zhou","doi":"10.1159/000526139","DOIUrl":"https://doi.org/10.1159/000526139","url":null,"abstract":"<p><strong>Introduction: </strong>Aged kidney is characterized by mitochondrial dysfunction, cellular senescence, and fibrogenesis. The activation of Wnt/β-catenin signaling plays an important role in the initiation of kidney aging. However, the inhibiting strategies have not been discovered in detail. Here, we compared the therapeutic effects of two β-catenin inhibitors, KYA1797K and ICG-001, to assess their superiority.</p><p><strong>Methods: </strong>Two-month-old male C57BL/6 mice which had undergone unilateral nephrectomy and received D-galactose (D-gal) injection were co-treated with KYA1797K or ICG-001 at 10 mg/kg/day for 4 weeks. Human proximal renal tubular cells were treated with D-gal and KYA1797K/ICG-001 to compare their effects.</p><p><strong>Results: </strong>Compared with ICG-001, which inhibits β-catenin pathway through blocking the binding of β-catenin and cAMP response element-binding protein (CREB)-binding protein (CBP), KYA1797K, a novel small molecule destabilizing β-catenin through activating Axin-GSK3β complex, possesses the superior effects on protecting against kidney aging. In D-gal-treated accelerated aging mice, KYA1797K could greatly inhibit β-catenin pathway, preserve mitochondrial homeostasis, repress cellular senescence, and retard age-related kidney fibrosis. In cultured proximal tubular cells, KYA1797K shows a better effect on inhibiting cellular senescence and could better suppress mitochondrial dysfunction and ameliorate the fibrotic changes, at the same dose as that in ICG-001.</p><p><strong>Conclusion: </strong>These results show that effectively eliminating β-catenin is a necessity to target against age-related kidney injury, suggesting the multiple transcriptional regulation of β-catenin in kidney aging besides T-cell factor/lymphoid enhancer-binding factor family of transcription factors (TCF/LEF-1).</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"8 5","pages":"408-423"},"PeriodicalIF":3.7,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/ad/kdd-0008-0408.PMC9710484.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35346349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Growth Factors: Potential Biomarkers and Therapeutic Targets in Kidney Diseases.","authors":"Wei Tang,&nbsp;Yufeng Zhang,&nbsp;Sijia Cui,&nbsp;Fan Yi","doi":"10.1159/000526208","DOIUrl":"https://doi.org/10.1159/000526208","url":null,"abstract":"<p><strong>Background: </strong>Kidney diseases are a prevalent health problem worldwide. Although substantial progress has been made in understanding the pathophysiology of kidney disease, currently there is no satisfactory clinical treatment available to prevent or treat kidney disease. Therefore, strategies to establish early diagnosis, identify the key molecules, and develop novel therapeutic interventions to slow the progression of kidney diseases and reduce their complications are encouraged.</p><p><strong>Summary: </strong>The growth factors play a crucial role in the development of kidney diseases. The altered levels of growth factors are usually detected in circulation and urine in the disease course. A growing body of studies has suggested that growth factors, receptors, and related regulators are promising biomarkers for the diagnosis and/or prognosis and potential therapeutic targets for the treatment of kidney diseases. In this review, we summarize recent advances in the potential applications of growth factors for diagnostic biomarkers and therapeutic targets in kidney diseases and highlight their performances in clinical trials.</p><p><strong>Key messages: </strong>Most diagnostic and therapeutic strategies targeting growth factors are still far from clinical implementation. The better understanding of growth factor-regulated pathophysiology and the progress of new intervention approaches are expected to facilitate the clinical translation of growth factor-based diagnosis and therapy of kidney diseases.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"8 5","pages":"368-380"},"PeriodicalIF":3.7,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/23/kdd-0008-0368.PMC9710479.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35207965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SENP3 Aggravates Renal Tubular Epithelial Cell Apoptosis in Lipopolysaccharide-Induced Acute Kidney Injury via deSUMOylation of Drp1.","authors":"Lirui Wang,&nbsp;Jiangtao Li,&nbsp;Chen Yu","doi":"10.1159/000525308","DOIUrl":"https://doi.org/10.1159/000525308","url":null,"abstract":"<p><strong>Background: </strong>Sepsis causes acute kidney injury (AKI) in critically ill patients, although the mechanisms underlying the pathophysiology are not fully understood. SUMO-specific proteases 3 (SENP3), a member of the deSUMOylating enzyme family, is known as a redox sensor and could regulate multiple cellular signaling pathways. However, the role of SENP3 in septic AKI remains unclear.</p><p><strong>Objectives: </strong>The purpose of this study was to investigate the role of SENP3 in lipopolysaccharide (LPS)-induced AKI model.</p><p><strong>Methods: </strong>C57BL/6 mice were given intraperitoneal injection of LPS (10 mg/kg). NRK-52E cells were treated with LPS in vitro. The SENP3 protein expression was analyzed by Western blotting. The levels of reactive oxygen species (ROS) in cells were measured using DCFH-DA. SENP3-siRNA or SENP3-plasmid was, respectively, transfected into NRK-52E cells to knock down or overexpress the SENP3 expression. Western blotting was performed to analyze the protein expression of cleaved caspase 3, cytochrome c, and dynamin-related protein 1 (Drp1). The mitochondrial membrane potential was measured using JC-1 assay kit. Co-immunoprecipitation was used to determine the interaction of Drp1 and SMUO2/3.</p><p><strong>Results: </strong>SENP3 protein expression was obviously increased in renal tissues from the mouse model of LPS-induced AKI. Accordingly, SENP3 expression was upregulated in NRK-52E cells treated with LPS in a ROS-dependent manner in vitro. Knockdown of SENP3 dramatically ameliorated LPS-induced apoptosis of NRK-52E cells, whereas overexpression of SENP3 further aggravated LPS-induced apoptosis of NRK-52E cells. Mechanistically, SENP3 triggered Drp1 recruitment to mitochondria by increasing the deSUMOylation of Drp1.</p><p><strong>Conclusion: </strong>SENP3 aggravated renal tubular epithelial cell apoptosis in LPS-induced AKI via Drp1 deSUMOylation manner.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"8 5","pages":"424-435"},"PeriodicalIF":3.7,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/0f/kdd-0008-0424.PMC9710481.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35207964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should More Patients with Kidney Failure Bring Treatment Home? What We Have Learned from COVID-19.","authors":"Xueqing Yu,&nbsp;Vivekanand Jha,&nbsp;Hidetomo Nakamoto","doi":"10.1159/000525046","DOIUrl":"https://doi.org/10.1159/000525046","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic is challenging healthcare systems worldwide and has placed hospitals and healthcare providers (HCPs) at the center of a global crisis. Disruptions to hospital priorities, and limitations placed on the mobility of societies, have contributed to changes in the way HCPs and patients view and access dialysis for kidney failure, including which dialysis modality is preferred.</p><p><strong>Summary: </strong>This article explores the dialysis experience within the COVID-19 pandemic environment in the Asia Pacific region and presents evidence that peritoneal dialysis (PD) provides benefits to patients, HCPs, and health systems. As the number of people infected with COVID-19 has increased, the advantages of PD as a dialysis modality for limiting the spread of COVID-19 infection has been recognized.</p><p><strong>Key message: </strong>The utility of PD has been demonstrated during the COVID-19 pandemic; thus, ensuring that the usage of PD is maintained and increased in a post-pandemic future is key. Such a scenario could enhance our ability to care for patients without interruption in circumstances of unforeseen obstacles and supports the ability of healthcare systems and patients to overcome barriers to dialysis access.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":" ","pages":"357-367"},"PeriodicalIF":3.7,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/8a/kdd-0008-0357.PMC9372457.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40723160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}